2014 Fiscal Year Final Research Report
Regulation of endoplasmic reticulum chaperone GRP78 expression in expanded polyglutamine diseases
| Project/Area Number |
23590094
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Biological pharmacy
|
|---|
| Research Institution | Kyoto Pharmaceutical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
HATAYAMA Takumi 京都薬科大学, 薬学部, 名誉教授 (10094484)
|
|---|
| Project Period (FY) |
2011-04-28 – 2015-03-31
|
| Keywords | 神経変性疾患 / 小胞体ストレス / ＧＲＰ７８ |
|---|
| Outline of Final Research Achievements |
Polyglutamine (polyQ) diseases are inherited neurodegenerative diseases characterized by the aggregation of proteins containing expanded polyQ tract. It has been shown that expanded polyQ tract-containing proteins impair the functions of other cellular proteins. In this study, (1) we found that the decreased GRP78 expression in the cells expressing EGFP-polyQ97 was due to the enhanced protein degradation of GRP78 through the ubiquitin-proteasome pathway, and (2) performed the screening for compounds that modulate the GRP78 expression in herbal medicines, and found that naringenin, one of the major constitutions of Kanzo (Glycyrrhizae Radix), induced the expression of GRP78 in several mammalian cells.
|
| Free Research Field |
生化学、細胞生物学
|
